NASDAQ:BTTX Better Therapeutics (BTTX) Stock Price, News & Analysis → The AI Defense Stock Set to Soar (From Behind the Markets) (Ad) Free BTTX Stock Alerts $0.01 +0.00 (+4.65%) (As of 11:56 AM ET) Add Compare Share Share Today's Range$0.0129▼$0.016050-Day Range$0.01▼$0.2252-Week Range$0.01▼$1.61Volume549,244 shsAverage Volume6.78 million shsMarket Capitalization$673,110.00P/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Better Therapeutics alerts: Email Address Better Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside46,053.8% Upside$6.00 Price TargetShort InterestBearish8.29% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.51Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.86) to ($0.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.02 out of 5 stars 3.3 Analyst's Opinion Consensus RatingBetter Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Better Therapeutics has a forecasted upside of 46,053.8% from its current price of $0.01.Amount of Analyst CoverageBetter Therapeutics has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.29% of the float of Better Therapeutics has been sold short.Short Interest Ratio / Days to CoverBetter Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Better Therapeutics has recently increased by 20.19%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBetter Therapeutics does not currently pay a dividend.Dividend GrowthBetter Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BTTX. Previous Next 3.1 News and Social Media Coverage News SentimentBetter Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Better Therapeutics this week, compared to 1 article on an average week.Search Interest51 people have searched for BTTX on MarketBeat in the last 30 days. This is an increase of 132% compared to the previous 30 days.MarketBeat Follows4 people have added Better Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Better Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders51.40% of the stock of Better Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 34.00% of the stock of Better Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Better Therapeutics are expected to grow in the coming year, from ($0.86) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Better Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Better Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.Here's how you can invest >>> About Better Therapeutics Stock (NASDAQ:BTTX)Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.Read More BTTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BTTX Stock News HeadlinesMarch 27, 2024 | americanbankingnews.comBetter Therapeutics (BTTX) Set to Announce Earnings on ThursdayMarch 21, 2024 | americanbankingnews.comBetter Therapeutics (NASDAQ:BTTX) versus Agape ATP (NASDAQ:ATPC) Financial ContrastMarch 28, 2024 | Behind the Markets (Ad)The AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.March 16, 2024 | uk.investing.comBetter Therapeutics plans employee layoffs, strategic reviewMarch 14, 2024 | markets.businessinsider.comDow Dips Over 100 Points; Dick's Sporting Goods Earnings Top ViewsMarch 14, 2024 | businesswire.comBetter Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from NasdaqMarch 5, 2024 | businesswire.comBetter Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health CentersMarch 4, 2024 | finance.yahoo.comBetter Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)March 28, 2024 | Behind the Markets (Ad)The AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.February 22, 2024 | finance.yahoo.comCAH Feb 2024 107.000 putFebruary 20, 2024 | benzinga.comWhy Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionFebruary 20, 2024 | marketwatch.comBetter Therapeutics Gets Breakthrough Device Designation For Cognitive Behavioral Therapy PlatformFebruary 20, 2024 | businesswire.comBetter Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver DiseaseFebruary 6, 2024 | markets.businessinsider.comBuy Rating on Astria Therapeutics Supported by STAR-0215’s Promising Market Potential and Favorable Trial ResultsFebruary 6, 2024 | marketwatch.comBetter Therapeutics Enters Rebate Agreement with Pharmacy Benefit ManagerFebruary 6, 2024 | finance.yahoo.comBetter Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes TreatmentJanuary 18, 2024 | finance.yahoo.comDavid Perry Bought 8.6% More Shares In Better TherapeuticsJanuary 17, 2024 | finance.yahoo.comBetter Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care AloneJanuary 16, 2024 | tmcnet.comBiora Therapeutics Provides Outlook for 2024January 3, 2024 | finance.yahoo.comBetter Therapeutics Insiders Added US$6.57m Of Stock To Their HoldingsJanuary 2, 2024 | msn.comBetter Therapeutics applies for FDA breakthrough designation for NASH deviceJanuary 2, 2024 | finance.yahoo.comBetter Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver DiseaseDecember 13, 2023 | msn.comBetter Therapeutics files to sell 20M shares of common stock for holdersDecember 12, 2023 | msn.comBetter Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?November 29, 2023 | msn.comBetter Therapeutics amends debt facility, implements cost-saving measuresNovember 28, 2023 | finance.yahoo.comBetter Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost ReductionsNovember 14, 2023 | finance.yahoo.comFrost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership AwardSee More Headlines Receive BTTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Better Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Next Earnings (Estimated)4/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Health services Sub-IndustryN/A Current SymbolNASDAQ:BTTX CUSIPN/A CIK1832415 Webmcacquisition.com Phone415-887-2311FaxN/AEmployees54Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$9.00 Low Stock Price Target$3.00 Potential Upside/Downside+46,053.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,760,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-217.46% Debt Debt-to-Equity RatioN/A Current Ratio0.57 Quick Ratio0.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-0.33Miscellaneous Outstanding Shares49,860,000Free Float24,233,000Market Cap$648,180.00 OptionableOptionable Beta2.35 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. David P. Perry M.B.A. (Age 56)Co-Founder & Executive Chairman Comp: $260kMr. Frank L. Karbe (Age 56)CEO, Interim CFO, President & Director Comp: $533.37kDr. Mark A. Berman M.D. (Age 49)Chief Medical Officer Comp: $573.75kMs. Kristin Wynholds (Age 52)Chief Product Officer Comp: $519.07kMr. Andres CamachoSenior VP of Technology & Head of EngineeringMs. Angela WillisSenior Vice President of Market AccessMs. Jessica MengChief Commercial OfficerLeslie MillerControllerMore ExecutivesKey CompetitorsAmpio PharmaceuticalsNYSE:AMPEBellerophon TherapeuticsNASDAQ:BLPHDMK PharmaceuticalsNASDAQ:DMKBellicum PharmaceuticalsNASDAQ:BLCMAclarionNASDAQ:ACONView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 301,743 shares on 3/11/2024Ownership: 0.397%Vanguard Group Inc.Sold 301,743 shares on 2/15/2024Ownership: 0.397%MMCAP International Inc. SPCSold 1,226,809 shares on 2/12/2024Ownership: 0.715%David P PerryBought 1,233,045 shares on 7/27/2023Total: $900,122.85 ($0.73/share)Andrew J ArmaninoBought 274,010 shares on 7/27/2023Total: $200,027.30 ($0.73/share)View All Insider TransactionsView All Institutional Transactions BTTX Stock Analysis - Frequently Asked Questions Should I buy or sell Better Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Better Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BTTX shares. View BTTX analyst ratings or view top-rated stocks. What is Better Therapeutics' stock price target for 2024? 3 equities research analysts have issued twelve-month price objectives for Better Therapeutics' stock. Their BTTX share price targets range from $3.00 to $9.00. On average, they predict the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 46,053.8% from the stock's current price. View analysts price targets for BTTX or view top-rated stocks among Wall Street analysts. How have BTTX shares performed in 2024? Better Therapeutics' stock was trading at $0.1950 at the start of the year. Since then, BTTX stock has decreased by 93.3% and is now trading at $0.0130. View the best growth stocks for 2024 here. Are investors shorting Better Therapeutics? Better Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 2,560,000 shares, an increase of 20.2% from the February 29th total of 2,130,000 shares. Based on an average trading volume of 6,410,000 shares, the short-interest ratio is presently 0.4 days. Approximately 8.3% of the shares of the stock are sold short. View Better Therapeutics' Short Interest. When is Better Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our BTTX earnings forecast. Who are Better Therapeutics' major shareholders? Better Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include MMCAP International Inc. SPC (0.71%), Vanguard Group Inc. (0.40%), Vanguard Group Inc. (0.40%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Andrew J Armanino, David P Perry, Elder Granger, Frank Karbe, Geoffrey M Parker, Kevin J Appelbaum, Mark A Berman, Mark Heinen and Risa J Lavizzo-Mourey. View institutional ownership trends. How do I buy shares of Better Therapeutics? Shares of BTTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BTTX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Better Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.